Key Points
- CEO Sanj Patel sold 151,300 shares for about $14.33 million at an average price of $94.71 under a pre-arranged Rule 10b5-1 plan; he retained 774,500 shares.
- Kiniksa beat quarterly expectations, reporting EPS of $0.56 versus $0.37 consensus and revenue of $285.97 million versus $260.66 million expected.
- Analysts maintain a Moderate Buy consensus with a $100.57 average price target; seven rate the stock Buy and two rate it Hold.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 151,300 shares of the company's stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total value of $14,329,623.00. Following the completion of the sale, the chief executive officer owned 774,500 shares in the company, valued at approximately $73,352,895. This represents a 16.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Performance
Shares of NASDAQ:KNSA opened at $93.86 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The stock has a market capitalization of $7.32 billion, a P/E ratio of 72.20 and a beta of 0.07. The stock has a 50-day simple moving average of $80.46 and a 200-day simple moving average of $61.36.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analysts' expectations of $260.66 million. Analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on KNSA. The Goldman Sachs Group raised their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an "outperform" rating in a research report on Wednesday, October 28th. Finally, Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.57.
Get Our Latest Stock Analysis on Kiniksa Pharmaceuticals International
Institutional Trading of Kiniksa Pharmaceuticals International
A number of hedge funds and other institutional investors have recently bought and sold shares of KNSA. JW Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $1,641,000. Russell Investments Group Ltd. raised its holdings in Kiniksa Pharmaceuticals International by 1,656.1% during the third quarter. Russell Investments Group Ltd. now owns 61,569 shares of the company's stock worth $4,594,000 after acquiring an additional 58,063 shares in the last quarter. Lisanti Capital Growth LLC raised its holdings in Kiniksa Pharmaceuticals International by 48.0% during the 3rd quarter. Lisanti Capital Growth LLC now owns 129,250 shares of the company's stock worth $9,643,000 after purchasing an additional 41,945 shares during the last quarter. Jacobi Capital Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth $48,000. Finally, Ethic Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at $726,000. Hedge funds and other institutional investors own 53.95% of the company's stock.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
